Gastroesophageal Junction Cancer

• CLINICAL_TRIALS trial_result · 2024-05-17
  Clinical Trial Update: Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: [Phase 3]

  Phase 3 clinical trial evaluating pembrolizumab in combination with the FLOT chemotherapy regimen for gastroesophageal junction cancer; the …

• CLINICAL_TRIALS trial_result · 2024-05-14
  Clinical Trial Update: JNT Versus TNT to Guided OGT-overlap Oesophagojejunostomy [NA]

  A completed clinical trial comparing JNT versus TNT methods to guide OGT-overlap oesophagojejunostomy in gastric and gastroesophageal juncti…

• CLINICAL_TRIALS research · 2024-05-07
  Clinical Trial Update: The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction [Phase 2]

  A Phase 2 neoadjuvant trial evaluating a combination of tislelizumab, anlotinib, S-1, and oxaliplatin for locally advanced adenocarcinoma of…

• CLINICAL_TRIALS trial_result · 2024-03-12
  Clinical Trial Update: KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 clinical trial update for KN026 in patients with HER2-expressing gastric/gastroesophageal junction cancer; study status completed.

• CLINICAL_TRIALS trial_result · 2023-10-12
  Clinical Trial Update: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) [Phase 3]

  Phase 3 trial MK-3475-859 (KEYNOTE-859) evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric/GEJ adenocarc…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2023-08-16
  Clinical Trial Update: Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer [Phase 2]

  Phase 2 clinical trial updating neoadjuvant toripalimab in gastric/gastroesophageal junction adenocarcinoma with dMMR/MSI-H status.

• CLINICAL_TRIALS trial_result · 2023-07-12
  Clinical Trial Update: Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial [Phase 2]

  An open-label Phase 2 trial evaluating continuation of serplulimab plus chemotherapy after first progression in advanced gastric or gastro-e…

• CLINICAL_TRIALS trial_result · 2023-05-19
  Clinical Trial Update: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating perioperative mFOLFOX plus pembrolizumab for gastroesophageal junction and stomach adenocarcinoma is currently acti…

• CLINICAL_TRIALS trial_result · 2023-05-10
  Clinical Trial Update: Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer [Phase 2]

  Phase 2 trial update evaluating surgical conversion with Candonilimab (AK104) plus Paclitaxel, S-1, and Apatinib for unresectable advanced g…

• CLINICAL_TRIALS trial_result · 2023-02-08
  Clinical Trial Update: An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients [Phase 2]

  Phase 2 open-label study of bavituximab plus pembrolizumab in advanced gastric and gastroesophageal junction cancer has completed with resul…

• CLINICAL_TRIALS trial_result · 2023-01-27
  Clinical Trial Update: Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer [Phase 2]

  Phase 2 clinical trial update for afatinib plus paclitaxel as second-line therapy in advanced gastric and gastroesophageal junction cancers.

• CLINICAL_TRIALS trial_result · 2022-11-08
  Clinical Trial Update: Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes [Phase 1, Phase 2]

  Exploratory Phase Ib/II trial evaluating first-line treatment for unresectable locally advanced/advanced gastric or gastroesophageal junctio…

• FDA approval · 2022-08-05
  FDA Approved: ENHERTU — Supplemental Application (Daiichi Sankyo Inc.)

  FDA approved a supplemental application for ENHERTU (fam-trastuzumab deruxtecan-nxki) from Daiichi Sankyo Inc. to update labeling and/or add…

• CLINICAL_TRIALS trial_result · 2022-08-04
  Clinical Trial Update: Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer [Phase 1, Phase 2]

  This ClinicalTrials.gov update reports results from a Phase 1/2 study evaluating the combination of margetuximab and pembrolizumab in advanc…

• CLINICAL_TRIALS trial_result · 2022-07-11
  Clinical Trial Update: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) [Phase 2, Phase 3]

  Phase 2/3 trial updating perioperative therapy for gastric or gastroesophageal junction cancer comparing FLOT versus FLOT with ramucirumab. …

• CLINICAL_TRIALS trial_result · 2022-06-28
  Clinical Trial Update: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer [Phase 3]

  Phase 3 efficacy trial comparing nivolumab plus ipilimumab or nivolumab plus chemotherapy against standard chemotherapy in gastric cancer an…

• CLINICAL_TRIALS trial_result · 2022-06-02
  Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 study investigating the safety and efficacy of Max-40279-01 in advanced gastric cancer or gastroesophageal junction cancer.

• CLINICAL_TRIALS trial_result · 2022-05-24
  Clinical Trial Update: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 trial updating bemarituzumab with modified FOLFOX6 in gastric/gastroesophageal junction cancer has completed with results posted in …

• CLINICAL_TRIALS trial_result · 2022-05-02
  Clinical Trial Update: HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer [Phase 2]

  Phase 2 trial update of HLX07+HLX10 with chemotherapy or HLX07 monotherapy in advanced/metastatic gastric/gastroesophageal junction cancer i…

• CLINICAL_TRIALS trial_result · 2022-04-11
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer [Phase 2]

  Phase 2 trial evaluating sintilimab plus apatinib and chemotherapy for HER-2 negative MSS advanced or metastatic gastric or gastroesophageal…

• CLINICAL_TRIALS trial_result · 2022-02-23
  Clinical Trial Update: A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. [Phase 2]

  Phase 2 clinical trial update for MRG002 in HER2-positive/HER2-low locally advanced or metastatic gastric/gastroesophageal junction cancer.

• CLINICAL_TRIALS trial_result · 2022-02-17
  Clinical Trial Update: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer [Phase 2]

  Phase 2 trial of ipatasertib with fluoropyrimidine plus oxaliplatin in advanced/metastatic gastric or gastroesophageal junction cancer compl…

• CLINICAL_TRIALS trial_result · 2022-02-16
  Clinical Trial Update: A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer [Phase 2]

  A Phase II clinical trial evaluating Fruquintinib combined with RC48 for previously treated HER2-positive locally advanced or metastatic gas…

• CLINICAL_TRIALS trial_result · 2022-01-26
  Clinical Trial Update: Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma [Phase 2]

  Phase 2 trial exploring camrelizumab with FOLFOX as neoadjuvant therapy for resectable gastric and gastroesophageal junctional adenocarcinom…

• CLINICAL_TRIALS trial_result · 2022-01-12
  Clinical Trial Update: DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) [Phase 2]

  The DESTINY-Gastric02 Phase 2 trial of DS-8201a (trastuzumab deruxtecan) in HER2-positive unresectable or metastatic gastric cancer has comp…